Drug Profile
XR 5000
Alternative Names: AC; Acridine carboxamide; DACA; NSC 601316; SN 22995Latest Information Update: 26 Feb 2001
Price :
$50
*
At a glance
- Originator Auckland Cancer Society Research Centre
- Developer Cancer Research UK; Xenova Group
- Class Antineoplastics
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Glioblastoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 26 Feb 2001 Discontinued-II for Glioblastoma in Europe (Infusion)
- 26 Feb 2001 Discontinued-II for Non-small cell lung cancer in Europe (Infusion)
- 26 Feb 2001 Discontinued-II for Ovarian cancer in Europe (Infusion)